about
Clozapine combined with different antipsychotic drugs for treatment resistant schizophreniaAntipsychotic Dose Mediates the Association between Polypharmacy and Corrected QT IntervalA translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyRelapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis.Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behaviorA review of pharmacologic strategies for switching to atypical antipsychoticsAugmentation of olanzapine in treatment-resistant schizophrenia.Polypharmacy in psychiatry: a review.Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceAntipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient HospitalsDoes the addition of a second antipsychotic drug improve clozapine treatment?Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.The Influence of Previous Antipsychotic Polypharmacy Versus Monotherapy on the Effectiveness of Antipsychotic after Switching to Paliperidone Extended-release.Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial.Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study.Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis.Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.
P2860
Q24240093-04FFCC1D-1CE7-49AB-84D4-FA4B3EE03C32Q28553078-8928813D-9472-416A-A13B-9EB62934D883Q30485065-60A47907-5828-490A-88F1-613698101501Q33818732-B044EABF-D557-4C2C-84AF-A6D3EEB7AF0EQ35175610-748BD417-D8C3-4DCE-B0CF-0A058353A8AEQ36199687-7E6BE72B-3456-434F-9E04-C9586BB40000Q36331244-D468E422-14F0-4DFE-ACC7-9C41601484F7Q36841579-7ED002A4-85DD-4A83-BFD6-646DD8D6CDCEQ36905083-45BE927B-F60A-4663-8F83-00892BCB632FQ37029622-83F519A7-A1C6-4F9B-B172-2D630423D46FQ37116547-39A7ABE4-CE12-4128-B02B-323F8EB26E22Q37147547-078E64E3-9013-4B0E-983E-F53A676F5A61Q37209442-96986493-C793-450A-96E4-C3E3B16F4263Q37216848-2741200E-940B-4104-ABF4-5B03303D1C55Q37500587-41AFE928-4A6B-49BF-ACC1-2F31071471D3Q37611162-04FB1B40-3CAC-4DDB-8262-1C050490DEFBQ38687957-8FD9AF61-C3A4-45F6-980D-77D983ACD50EQ39043789-A11E727E-BD64-4171-BED6-4D5134F0D03FQ41064310-4BF65B51-05AB-46F8-B5CF-121405482A64
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinicians' reasons for antipsychotic coprescribing.
@ast
Clinicians' reasons for antipsychotic coprescribing.
@en
type
label
Clinicians' reasons for antipsychotic coprescribing.
@ast
Clinicians' reasons for antipsychotic coprescribing.
@en
prefLabel
Clinicians' reasons for antipsychotic coprescribing.
@ast
Clinicians' reasons for antipsychotic coprescribing.
@en
P356
P1476
Clinicians' reasons for antipsychotic coprescribing
@en
P2093
Michael J Sernyak
Robert Rosenheck
P304
P356
10.4088/JCP.V65N1203
P577
2004-12-01T00:00:00Z